KRAS and neoplasm: Indeed, the effects of tumor suppressor inactivation on growth across oncogenic KRAS-, BRAF-, and EGFR-driven tumors were uncorrelated (Fig. 4C, D; Spearman ρ = 0.41 for BRAF versus G12C, ρ = 0.14 for EGFR versus G12C).